NCT01336686View on ClinicalTrials.gov

Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout

PHASE2CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
HyperuricemiaGout
Interventions
DRUG

Arhalofenate

Arhalofenate 400 mg once daily for 4 weeks

DRUG

Arhalofenate

Arhalofenate 600 mg once daily for 4 weeks

DRUG

Placebo comparator

Matching placebo once daily for 4 weeks

DRUG

Colchicine

0.6 mg colchicine daily for flare prophylaxis

Trial Locations (12)

Unknown

Tucson

Los Angeles

Boca Raton

Jupiter

Tampa

Honolulu

Wheaton

St Louis

New York

Raleigh

Cincinnati

West Jordan

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT01336686 - Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout | Biotech Hunter | Biotech Hunter